Recruiting
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite GLP-1-based therapy.
ClinicalTrials.gov IDNCT07502508
PhasePHASE2
Enrollment60
SponsorBiomea Fusion Inc.
Age18 Years – 75 Years
SexALL
Conditions studied
Type 2 Diabetes
About this study
This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite GLP-1-based therapy.
Interventions
- Drug: icovamenib 100 mg — icovamenib 100 mg
- Drug: Placebo — Matching placebo
Primary outcomes
- To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic control (26 weeks)
Eligibility information
Key Inclusion Criteria:
1. Males or females, age ≥18 years and ≤75 years
2. Have been diagnosed with T2D
3. Taking FDA-approved GLP-1 based therapy (administered as subcutaneous injection) and have been treated with lifestyle management and 0 to 2 additional antihyperglycemic medications (metformin and/or SGLT2 inhibitor) with a stable dose of all medications for at least 3 months prior to screening
4. Have HbA1c ≥7.0 and ≤10.5%
5. Have a BMI 25 to 45 kg/m2
6. Female participants of childbearing potential must have a negative pregnancy test, must be non-lactating, must be willing to have additional pregnancy tests during the study, must agree to the sex and contraception requirements.
7. Willing and able to provide written, signed informed consent and be willing and able to comply with all study procedures and tests.
Key Exclusion Criteria:
1. Have type 1 diabetes mellitus or a secondary form of diabetes
2. Have a history of diabetic ketoacidosis or hyperosmolar coma in the 6 months prior to screening
3. Have a history of severe hypoglycemia (defined by the occurrence of hypoglycemia symptoms requiring the assistance of another person for recovery) in the 6 months prior to screening or a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms as judged by the investigator
4. Have personal or family history (first-degree relative) of MEN1 or MEN2 or medullary thyroid carcinoma
5. Use of any of the following in the 3 months prior to screening: compounded GLP-1-based therapy, sulfonylureas, meglitinides, thiazolidinediones, alpha glucosidase inhibitor, DPP4I, bile acid sequestrants, dopamaine-2 agonists, amylin, or insulin
Study locations
- Central Research Associates, LLC dba Flourish Research, Birmingham, Alabama 35205 United States
- Hope Clinical Research, Canoga Park, California 91303 United States
- Ark Clinical Research, Long Beach, California 90815 United States
- Catalina Research Institute, LLC, Montclair, California 91763 United States
- Paradigm Clinical Research Centers, LLC, San Diego, California 92108 United States
- Southwest General Healthcare Center, Fort Myers, Florida 33907 United States
- Panax Clinical Research, Miami Lakes, Florida 33014 United States
- Flourish Research Orlando, Winter Park, Florida 32789 United States
- Centricity Research, Endocrine Consultants PC, Columbus, Georgia 31904 United States
- David Kavtaradze MD, Inc, Cordele, Georgia 31015 United States
Showing 10 of 20 reported sites. See the official listing for all locations.
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-18.